Erlotinib for Treatment of Psoriasis

Inclusion Criteria:

Clinical diagnosis of moderate to severe psoriasis
Must have documented moderate to severe psoriasis by the Physician's Global Assessment (PGA) and the Psoriasis Area Severity Index (PASI)
Must be able to swallow tablets
Must be able to provide written informed consent
Subjects with reproductive potential (menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures throughout the study and thirty days after discontinuation of study drug. Women of childbearing potential must provide negative pregnancy test (serum or urine) within 14 days prior to randomization.

Exclusion Criteria:

Use of concurrent agents/therapies for psoriasis
Bilirubin > 3 X ≥ ULN or moderate to severe hepatic impairment
Pregnant or breast-feeding females
Subjects currently receiving other anticancer treatments
Subjects currently receiving other biologic treatments
Subjects currently receiving blood thinners (warfarin or heparin)
Subjects who currently smoke
Subjects with other skin disease which in the opinion of the investigator, would inhibit the ability to use the PGA and PASI evaluation methods